Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of
MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line
treatment setting in patients with CRC with KRAS G12C mutation.
Phase
Phase 3
Funding Agency/Sponsor
Industrial
Disease
Colorectal Cancer
Enrollment Eligibility
Inclusion Criteria:
- Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in
tumor tissue.
- Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based
chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically
documented progression of disease on or after treatment.
Exclusion Criteria:
- Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
- Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
- Active brain metastasis